Semaglutide Injection — once-weekly GLP-1 receptor agonist for type 2 diabetes glycaemic control and chronic weight management. GMP manufact
Semaglutide Injection — once-weekly GLP-1 receptor agonist for type 2 diabetes glycaemic control and chronic weight management. GMP manufactured by Artemisine Medicines Technology with validated cold-chain supply, COA, COPP, DMF and CTD dossiers for global registration.
| Product Name | Semaglutide Injection (GLP-1 Receptor Agonist) |
|---|---|
| Dosage Form | Injection |
| Strength | 1.34 mg/mL — 1.5 mL & 3 mL prefilled pen |
| Standards | BP / ENTERPRISE |
| Packing | Prefilled pen, 1 pen/box; cold-chain 2–8°C shipping |
| Documents | COA, COPP, DMF, CTD Dossiers |
| MOQ | Contact us for MOQ and current stock |
Reference information summarised from WHO prescribing guidance. Expand each item below — clinical use must always follow the locally approved product insert.
Reference: WHO Model Formulary / WHO Model List of Essential Medicines. For professional reference only — clinical use must follow the locally approved product insert and national treatment guidelines.
Full batch testing and quality traceability under standard GMP workshops.
Sufficient stock on regular items, familiar with export logistics to 50+ countries.
COA, DMF, dossier and legalization documents for your market registration.